Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17189669 | 1.00 | KDM1A (0.52) | KDM1ASLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL25004706 | 1.00 | KDM1A (0.52) | KDM1ASLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL21503510 | 1.00 | KDM1A (0.52) | KDM1ASLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL24974216 | 1.00 | KDM1A (0.52) | KDM1ASLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL15254824 | 0.84 | KDM1A (0.53) | KDM1ASLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL17781846 | 0.84 | KDM1A (0.53) | KDM1ASLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL15254685 | 0.84 | KDM1A (0.53) | KDM1ASLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL25005430 | 0.80 | CHRNA7 (0.33) | KDM1ASLC6A3 | |
| SCHEMBL23995488 | 0.79 | MDM2 (0.49) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C | |
| SCHEMBL16232192 | 0.79 | KDM1A (0.52) | KDM1ASLC6A2SLC6A4SLC6A3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493451-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2016-11-15 | — | — | US | disclosed |
| US-20140336198-A1 | Amine Derivatives as Potassium Channel Blockers | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336198-A1 | Amine Derivatives as Potassium Channel Blockers | KCNA3, KCNH3, KCNK3 | KDM1A 285/4885SLC6A2 478/4885SLC6A4 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.